📰 2 sources covering this story

Trump’s FDA nominee could renew scrutiny to abortion drug risk: pro-life org CEO

First covered 7 hrs ago · latest take 1 hrs ago. Compare how each outlet is covering it — and rate the sources you trust.

"I think she's going to bring objectivity to the issue of mifepristone in a way that will expose this drug for the damage it causes women."

Fox News🏁 first to report7 hrs ago

Trump's FDA nominee Heidi Overton could bring renewed scrutiny to mifepristone, says Americans United for Life CEO who calls her a "pro-life" pick.